SARS-CoV-2 JN.1 variant evasion of IGHV3-53/3-66 B cell germlines
Science Immunology,
Journal Year:
2024,
Volume and Issue:
9(98)
Published: Aug. 9, 2024
The
severe
acute
respiratory
syndrome
coronavirus
2
variant
JN.1
recently
emerged
as
the
dominant
despite
having
only
one
amino
acid
change
on
spike
(S)
protein
receptor
binding
domain
(RBD)
compared
with
ancestral
BA.2.86,
which
never
represented
more
than
5%
of
global
variants.
To
define
at
molecular
level
ability
to
spread
globally,
we
interrogated
a
panel
899
neutralizing
human
monoclonal
antibodies.
Our
data
show
that
single
leucine-455-to-serine
mutation
in
RBD
unleashed
JN.1,
likely
occurring
by
elimination
70%
antibodies
mediated
IGHV3-53/3-66
germlines.
However,
resilience
class
3
low
neutralization
potency
but
strong
Fc
functions
may
explain
absence
disease.
Language: Английский
Comparison of effectiveness and safety of molnupiravir versus sotrovimab for COVID‐19: A systematic review and meta‐analysis
Immunity Inflammation and Disease,
Journal Year:
2024,
Volume and Issue:
12(4)
Published: April 1, 2024
This
systematic
review
and
meta-analysis
aimed
to
compare
the
effectiveness
safety
of
molnupiravir
sotrovimab
in
treatment
patients
with
coronavirus
disease
2019
(COVID-19).
Language: Английский
Sotrovimab lost neutralization efficacy against SARS-CoV-2 subvariants but remained clinically effective: Were monoclonal antibodies against COVID-19 rejected too early?
Journal of Infection and Public Health,
Journal Year:
2024,
Volume and Issue:
17(9), P. 102512 - 102512
Published: Aug. 7, 2024
Language: Английский